{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:09:36Z","timestamp":1772856576555,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1038\/s41391-022-00605-7","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T09:04:08Z","timestamp":1665565448000},"page":"162-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-4505","authenticated-orcid":false,"given":"Gijs P. A.","family":"van den Bergh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8908-1684","authenticated-orcid":false,"given":"Malou C. P.","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-1831","authenticated-orcid":false,"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja K. H.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-1869","authenticated-orcid":false,"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reindert J. A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-6586","authenticated-orcid":false,"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonsus J. M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5223-2549","authenticated-orcid":false,"given":"Andr\u00e9 M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonsus C. M.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"605_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant Prostate Cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"},{"key":"605_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","volume":"339","author":"M Eisenberger","year":"1998","unstructured":"Eisenberger M, Blumenstein B, Crawford E, Miller G, McLeod D, Loehrer P, et al. Bilateral orchiectomy with or without flutamide for metastatic Prostate Cancer. N. Engl J Med. 1998;339:1036\u201342.","journal-title":"N. Engl J Med"},{"key":"605_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","volume":"65","author":"C Pezaro","year":"2014","unstructured":"Pezaro C, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant Prostate Cancer. Eur Urol. 2014;65:270\u20133.","journal-title":"Eur Urol"},{"key":"605_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.euf.2016.09.008","volume":"4","author":"H Westgeest","year":"2018","unstructured":"Westgeest H, Uyl-de Groot C, van Moorselaar R, de Wit R, van den Bergh A, Coenen J, et al. Differences in trial and real-world populations in the Dutch Castration-resistant Prostate Cancer Registry. Eur Urol Focus. 2018;4:694\u2013701.","journal-title":"Eur Urol Focus"},{"key":"605_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.euf.2016.08.007","volume":"3","author":"C Whitney","year":"2017","unstructured":"Whitney C, Howard L, Posadas E, Amling C, Aronson W, Cooperberg M, et al. In men with castration-resistant Prostate Cancer, visceral metastases predict shorter overall survival: what predicts visceral metastases? Results from the SEARCH database. Eur Urol Focus. 2017;3:480\u20136.","journal-title":"Eur Urol Focus"},{"key":"605_CR6","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi S, Kelly W, Ma H, Zhou H, Solomon N, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with Castration-Resistant Prostate Cancer. J Clin Oncol. 2016;34:1652\u20139.","journal-title":"J Clin Oncol"},{"key":"605_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.clgc.2015.01.008","volume":"13","author":"J van Dodewaard-de Jong","year":"2015","unstructured":"van Dodewaard-de Jong J, Verheul H, Bloemendal H, de Klerk J, Carducci M, van den Eertwegh A. New treatment options for patients with metastatic Prostate Cancer: what is the optimal sequence? Clin Genitourin Cancer. 2015;13:271\u20139.","journal-title":"Clin Genitourin Cancer"},{"key":"605_CR8","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant Prostate Cancer. N. Engl J Med. 2020;383:2345\u201357.","journal-title":"N. Engl J Med"},{"key":"605_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.annonc.2021.03.205","volume":"32","author":"M Annala","year":"2021","unstructured":"Annala M, Fu S, Bacon J, Sipola J, Iqbal N, Ferrario C, et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021;32:896\u2013905.","journal-title":"Ann Oncol"},{"key":"605_CR10","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg C, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic Prostate Cancer. N. Engl J Med. 2019;381:2506\u201318.","journal-title":"N. Engl J Med"},{"key":"605_CR11","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","volume":"20","author":"PG Corn","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial. Lancet Oncol. 2019;20:1432\u201343.","journal-title":"Lancet Oncol"},{"key":"605_CR12","doi-asserted-by":"crossref","unstructured":"White I, Royston P, Wood A. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2010;30:377\u201399.","DOI":"10.1002\/sim.4067"},{"key":"605_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/cncr.29748","volume":"122","author":"B Hanyok","year":"2015","unstructured":"Hanyok B, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, et al. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the shared equal access Regional Cancer Hospital Database. Cancer. 2015;122:222\u20139.","journal-title":"Cancer"},{"key":"605_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1200\/JCO.2019.37.7_suppl.210","volume":"37","author":"E Shenderov","year":"2019","unstructured":"Shenderov E, Velho P, Awan A, Mirkheshti N, Eisenberger M, Pardoll D, et al. Genomic characterization of pulmonary-metastatic prostate cancer: a unique molecular subtype. J Clin Oncol. 2019;37:210\u201310.","journal-title":"J Clin Oncol"},{"key":"605_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41391-021-00486-2","volume":"25","author":"M Alshalalfa","year":"2022","unstructured":"Alshalalfa M, Seldon C, Franco I, Vince R, Carmona R, Punnen S, et al. Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer and Prostatic Dis. 2022;25:366\u20139.","journal-title":"Prostatic Dis"},{"key":"605_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","volume":"32","author":"S Halabi","year":"2014","unstructured":"Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant Prostate Cancer. J Clin Oncol. 2014;32:671\u20137.","journal-title":"J Clin Oncol"},{"key":"605_CR17","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/jnci\/djt280","volume":"105","author":"S Halabi","year":"2013","unstructured":"Halabi S, Lin C, Small E, Armstrong A, Kaplan E, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant Prostate Cancer survival in men treated with second-line chemotherapy. JNCI J Natl Cancer Inst. 2013;105:1729\u201337.","journal-title":"JNCI J Natl Cancer Inst"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00605-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00605-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00605-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T11:05:17Z","timestamp":1679051117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00605-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00605-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"17 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GPAvdB and MCPK report no conflict of interest. HMW reports travel expenses from Astellas and Ipsen; honoraria from Astellas and Roche. NM reports advisory role for Astellas, AstraZeneca, Janssen, JNJ, MSD, Pfizer, and Roche; funding (institutional and\/or personal) from Astellas, Janssen and Pfizer; research grants (institutional) from AstraZeneca and BMS; coordinating PI (institutional) for BMS and Jansen; and non-financial interests (leadership-role or PI) in Castration-resistant Prostate Cancer Registry, Dutch Uro-Oncology Study Group and Prospective Bladder Cancer Infrastructure (Netherlands). WRG reports speaker fees (institutional and\/or personal) from MSD; advisory role (institutional) for Bristol-Myers Squibb and Bayer; research grants (institutional) from Astellas, Bayer, Janssen-Cilag and MSD. KKHA reports no conflict of interest. IMvO reports conflicts of interest for Astellas, Bayer, Jansen, MSD\/Astra and AAA Novartis. RJAvM reports conflicts of interest for Astellas, AstraZeneca, Bayer, Janssen, Pantarhei Oncology and Sanofi-Genzyme. DMS reports research grants\/funding (institution) from Astellas, Besins and Dutch Cancer Society; Advisory\/consultancy role for Astellas, Janssen, Bayer and MSD; contracted research (institution) for Janssen, Eli Lilly, Astellas, Blue Earth Diagnostics, Bayer, SPL medical and QED therapeutics. AJMvdE reports study grants from Sanofi, Roche, Bristol-Myers Squibb, TEVA and Idera; travel expenses from MSD Oncology, Roche, Pfizer and Sanofi; speaker honoraria from Bristol-Myers Squibb and Novartis; advisory role for Bristol-Myers Squibb, MSD Oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, Merck and Pierre Fabre. AMB reports conflicts of interest for Astellas, Sanofi, Bayer and Janssen. ACMvdB and CAUdG report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}